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Hsp90 inhibition as a means to 
inhibit activation of the NLRP3 
inflammasome
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Natasha Josifovska4, Goran Petrovski4,5, Kai Kaarniranta3,6 & Anu Kauppinen  1
Once activated, the intracellular receptor NLRP3 assembles an inflammasome protein complex that 
facilitates the caspase-1-mediated maturation of IL-1β and IL-18. Inactive NLRP3 is guarded by a 
protein complex containing Hsp90. In response to stress stimuli, Hsp90 is released, and NLRP3 can be 
activated to promote inflammation. In this study, we blocked Hsp90 with geldanamycin and studied 
the fate of NLRP3 in human retinal pigment epithelial (RPE) cells. RPE cells play a central role in the 
development of age-related macular degeneration (AMD), a progressive eye disease causing severe 
vision loss in the elderly. IL-1α-primed ARPE-19 cells, human embryonal stem cell (hESC)-derived RPE 
cells, and primary human RPE cells were exposed to MG-132 and bafilomycin A to activate NLRP3 via 
the inhibition of proteasomes and autophagy, respectively. Additionally, RPE cells were treated with 
geldanamycin at different time points and the levels of NLRP3 and IL-1β were determined. Caspase-1 
activity was measured using a commercial assay. Geldanamycin prevented the activation of the 
inflammasome in human RPE cells. NLRP3 released from its protective complex became degraded by 
autophagy or secreted from the cells. Controlled destruction of NLRP3 is a potential way to regulate the 
inflammation associated with chronic diseases, such as AMD.
The nucleotide-binding domain and Leucine-rich repeat Receptor containing a Pyrin domain 3 (NLRP3) 
inflammasome is an intracellular signaling complex involved in the induction of inflammation1. NLRP3 is a 
pattern-recognition receptor (PRR) that becomes activated in a two-step process. In the priming step, there is ini-
tiation of the production of NLRP3 protein and the inactive pro-form of the pro-inflammatory cytokine IL-1β e.g. 
via the NF-κB signaling triggered by Toll-like receptor (TLR), nucleotide-binding oligomerization domain-like 
receptors (NOD) receptor, or cytokine receptor activation2,3. Thereafter, a wide variety of danger signals of both 
endogenous and exogenous origins can serve as activators for NLRP34–6. Activation results in the oligomerization 
of NLRP3 followed by the recruitment of the adaptor protein apoptosis-associated speck-like protein containing 
CARD (ASC) and the pro-caspase-1 into the complex, finally resulting in the auto-activation of caspase-11. The 
activated enzyme then cleaves the pro-forms of inflammatory cytokines, IL-1β and IL-18, into their mature forms 
that can be secreted out of the cell (Fig. 1).
Low-level inflammation is an integral component of many chronic diseases, and activation of the NLRP3 
inflammasome has recently also been associated with the pathogenesis of age-related macular degeneration 
(AMD)7–9. AMD is the leading cause of blindness among the elderly in the developed countries10. Prolongation 
of the life expectancies of the population will further increase the prevalence of AMD, emphasizing not only the 
personal suffering but also representing a financial, and societal health care burden11. New therapy options are 
urgently needed since there is no treatment available for the majority of patients12.
Heat shock protein 90 (Hsp90) is a multifunctional molecular chaperone that regulates the stability and the acti-
vation of several proteins (clients) related to signal transduction, protein trafficking, immunity, and receptor mat-
uration13. NLRP3 has also emerged as one of the Hsp90 clients. In conjunction with the ubiquitin ligase-associated 
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protein suppressor of the G2 allele of SKP1 (SGT1), Hsp90 forms a complex with NLRP3 and retains the 
receptor protein in an inactive but competent form for activation after reception of the priming signal14–16. 
If this complex is not formed, then the NLRP3 protein will be degraded, but it is far from clear whether the degra-
dation takes place in proteasomes or via the lysosomal (autophagy) pathway14,17. In the present study, the effects 
of the Hsp90 inhibitor geldanamycin (GA) on the fate of NLRP3 were explored in human RPE cells.
Methods
Cells and stimulations. ARPE-19 cells (American Type Culture Collection (ATCC), Manassas, VA, USA) 
were cultured under standard conditions in a humidified 5% CO2 atmosphere at 37 °C in Dulbecco’s modified 
Eagle’s medium (DMEM) and nutrient mixture F-12 1:1 mixture (Life Technologies, Carlsbad, CA, USA) contain-
ing 10% inactivated FBS (Thermo Fisher Scientific, Waltham, MA, USA), 100 units ml−1 penicillin, 100 µg ml−1 
streptomycin, and 2 mM L-glutamine (all Lonza, Basel, Switzerland). For experiments, cells were placed on 
12-well plates at a concentration of 200,000 cells ml−1 per well in serum-containing medium, and incubated for 
three days. Confluent cell cultures were washed with serum-free DMEM/F12 medium and primed with recom-
binant IL-1α (4 ng ml−1, R&D Systems, Abington, UK) in serum-free medium. After 24 h incubation, the cells 
were exposed to MG-132 (5 µM, Calbiochem, San Diego, CA, USA) for 24 h. The cells were further stimulated 
with bafilomycin A1 (BafA, 50 nM) or chloroquine (CHQ, 20 µM, both, Sigma-Aldrich, Munich, Germany) for 
an additional 24 h. The selected concentrations are based on our previous studies18. Where indicated, geldana-
mycin (GA; 0.25 µM, Calbiochem) was added to the cell cultures just before MG-132 or BafA, or six hours after 
BafA. Cell culture medium as well as cell lysates were collected after incubation for 24 h as described below. GA, 
MG-132, and BafA were solubilized in DMSO (Sigma-Aldrich).
Human embryonic stem cell-derived RPE cells (hESC-RPE). The hESC line Regea08/017 (46;XX) 
previously derived19 in our laboratory at BioMediTech, University of Tampere was used in this study. The undif-
ferentiated hESCs were cultured in the hESC culture medium consisting of KnockOut DMEM supplemented with 
20% KnockOut Serum Replacement (ko-SR), 2 mM Glutamax, 0.1 mM 2-mercaptoethanol (all Thermo Fisher 
Scientific), 1% Non-essential amino acids, 50 U ml−1 penicillin/streptomycin (both Lonza), and 8 ng ml−1 human 
basic fibroblast growth factor (bFGF, Peprotech) on inactivated human foreskin fibroblast feeder cells (CRL-2429, 
ATCC). Undifferentiated stem cell colonies were passaged mechanically or with TrypLE Select (Thermo Fisher 
Scientific) onto a fresh feeder cell layer every 6 to 10 days. The hESC line is routinely karyotyped and character-
ized for self-renewal and differentiation capacities as well as checking for the absence of mycoplasma.
The hESCs were differentiated to RPE as previously described20. Briefly, hESCs were cultured as floating cell 
aggregates in Low Cell Binding Surface Dishes (Nunc) in RPE basic medium consisting of the same reagents 
as the hESC medium except that it contained 15% ko-SR but no bFGF. For enrichment, pigmented cells were 
isolated and seeded onto human placental collagen IV (5 µg cm−2, Sigma-Aldrich)-coated culture plates. The 
use of human embryos for research purposes at BioMediTech has been approved by the National Authority 
for Medicolegal Affairs Finland (Dnro 1426/32/300/05). The institute also has supportive statements from the 
Ethical Committee of the Pirkanmaa Hospital District to derive, culture, and differentiate hESC lines (Skottman/
R05116). No new cell lines were derived for this study.
Primary human RPE cells. Primary human RPE cells were isolated from cadavers without known ocular 
diseases following the Guidelines of the Declaration of Helsinki. The study was approved by the Regional Ethics 
Figure 1. Activation of the NLRP3 inflammasome as a two-step process. After a priming signal NLRP3 protein 
is synthesized and protected from degradation by a protein complex containing Hsp90. After a second signal, 
NLRP3 is released from its chaperone, oligomerizes and recruits the receptor protein ASC and pro-Caspase-1 to 
form the NLRP3 inflammasome. Auto-activation of caspase-1 subsequently leads to the cleavage of pro-IL-1β 
and pro-IL-18 into their active forms.
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Committee of the Medical and Health Science Center (IREC), University of Debrecen, Hungary (DEOEC RKEB/
IKEB Prot. No. 3093-2010). The EU Directive 2004/23/EC on presumed consent practice for tissue collection is 
applied in Hungary and pertains to the samples collected for and used in the experiments approved by the IREC. 
The isolation of primary human RPE cells was started by removing the anterior segment (corneo-scleral ring) 
and the lens. Next, the vitreous and the neuroretina were removed using paper sponges and forceps, respectively. 
The RPE layer was carefully scraped using half-spherically bent-end Pasteur glass pipettes without damaging the 
Bruch’s membrane. The cell suspension was placed in PBS (Sigma-Aldrich) and centrifuged for 10 min at 200 × g, 
as described previously21. Cells were re-suspended in the DMEM Nutrient mixture F12 medium (Sigma-Aldrich) 
supplemented with 10% FBS (Gibco, Paisley, UK), 200 mM L-glutamine (Sigma-Aldrich), and 1% antibiotic/anti-
mycotic solution (Gibcon), and incubated on cell culture plates in a humidified CO2 atmosphere. Experiments 
were performed on passage 0 confluent cultures containing 2.5 × 105 cells per well. The cells were exposed to 
IL-1α, MG-132, and BafA using the same protocol as for ARPE-19 cells. Cell culture medium samples were col-
lected for IL-1β release measurements and three parallel samples/group were analysed accordingly.
Sample preparation. Medium samples and cell lysates were collected 24 h after the BafA treatment. Cells 
were rinsed with Dulbecco’s phosphate buffered saline (DPBS, Lonza)) before lysis with the specific buffer 
required for the caspase-1 activity assay. Cell lysates were centrifuged (16 060 × g, 10 min) and the superna-
tants were transferred into clean tubes. Protein concentrations were measured by the Bradford method from cell 
lysates22. Both medium samples and cell lysates were stored at −70 °C until analyzed.
ELISA measurements. The extracellular concentration of the pro-inflammatory cytokine IL-1β was determined 
using a specific BD OptEIATM human ELISA kit (BD, Franklin Lakes, NJ, USA). Additionally, the levels of NLRP3 were 
measured using a commercial ELISA kit (Cusabio, Wuhan, China) according to the manufacturer’s instructions.
Caspase-1 activity assay. The caspase-1 activity was measured from cell lysates using a commercial kit 
(R&D Systems) according to the manufacturer’s protocol. Results were normalized to protein concentrations.
Western blot. For detecting NLRP3, 20 µg of protein in whole-cell lysates was mixed with 4× protein loading 
solution (Life Technologies) supplemented with 5% β-mercaptoethanol. Samples were run in 15% SDS–PAGE 
gels and wet-blotted overnight onto nitrocellulose membranes (Amersham, Piscatawy, NJ, USA). The membranes 
were blocked for 2 h in 5% fat-free milk in 0.1% Tween-20/Tris buffered saline (TBS; 50 mM Tris, 150 mM NaCl) 
at room temperature (RT). The blocking buffer without milk was also used as a washing buffer and as a diluent 
for the primary and secondary antibodies. Thereafter, the membranes were incubated overnight at +4 °C with 
a rabbit monoclonal NLRP3 antibody (1:1000, Abcam, Cambridge, UK). After washing three times for 5 min, 
the membranes were incubated for 2 h at RT with horseradish peroxidase-conjugated anti-rabbit IgG antibody 
(1:5000, Life Technologies). Before detection, the membranes were washed as described above. Protein/antibody 
complexes were detected with an enhanced chemiluminescent (ECL) assay for horseradish peroxidase (Millipore, 
Billerica, MA, USA) on Super Rx medical X-ray film (Fuji Corporation, Tokyo, Japan). The band intensities were 
quantified using the ImageJ software (U. S. National Institutes of Health, Bethesda, MD, USA; http://rsb.info.nih.
gov/ij) and normalized to α-tubulin values using mouse monoclonal α-tubulin (Sigma-Aldrich) with polyclonal 
HRP-conjugated sheep anti-mouse IgG antibody (GE Healthcare, Fairfield, CT, USA).
Data and statistical analysis. The data and statistical analysis in this study comply with the recom-
mendations on experimental design and analysis in pharmacology23. Statistical analyses were conducted using 
GraphPad Prism 6.02 (Graphpad Software, San Diego, CA). Pairwise comparisons were performed using the 
Mann–Whitney U-test, and P-values of 0.05 or less were considered significant and sub-divided into three cat-
egories indicated with one, two, or three asterisks (*P < 0.05, **P < 0.01, ***P < 0.001). Each experiment was 
commonly repeated at least three times but depending on the experimental settings, some results in the present 
study were repeated up to seven times, and all data were utilized. In certain cases, the number of repetitions may 
have been restricted due to e.g. limited amounts of materials, such as available hESC-RPE and primary human 
RPE cells produced for this study.
Results
IL-1α efficiently primes RPE cells for the MG-132 + BafA-induced inflammasome activation. 
We have previously shown that inhibition of the intracellular clearance systems with MG-132 and BafA activates 
NLRP3 inflammasomes, leading to the secretion of IL-1β from ARPE-19 cells18. Although the inflammasome 
was activated without any additional signal e.g. through TLR or cytokine receptors, in this study, we provided the 
cells with an additional priming signal using IL-1α that activates the IL1B promoter via the NF-κB signaling path-
way3. IL-1α priming alone induced only 1.8 times higher IL-1β secretion when compared to untreated ARPE-19 
cells (Fig. 2a). BafA triggered a 2.4-fold increase, whereas MG-132 evoked a 10.8-fold increase in the amounts 
of secreted IL-1β, when compared to primed cells alone (not shown in Fig. 2). When administered together, 
MG-132 and BafA further enhanced the IL-1β secretion to 13.7-fold when compared to primed cells (Fig. 2a). 
These data indicate that priming alone does not activate the inflammasome but potentiates the effects of MG-132 
and BafA. In our previous study, the secreted IL-1β levels induced by MG-132 + BafA remained below 0.2 pg/ml 
but in the present study, the same activators on primed ARPE-19 cells raised the levels of released cytokine up to 
3.4 ± 0.18 pg/ml (mean ± SEM).
In order to demonstrate that there was inflammasome activation in other RPE cells in addition to ARPE-19, 
hESC–RPEs and primary human RPE cells were stimulated in a similar manner. An exposure of IL-1α-primed 
hESC-RPE cells to MG-132 + BafA treatment significantly increased the IL-1β levels when compared to con-
trol cells (Fig. 2b; 5.1 ± 0.5 pg ml−1 vs. 0.8 ± 0.1 pg ml−1). MG-132 + BafA induced a 3.8 times higher IL-1β 
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release also from IL-1α-pre-treated primary human RPE cells when compared to primed cells alone (Fig. 2c; 
30.2 ± 12.0 pg ml−1 vs. 8.0 ± 2.6 pg ml−1). It is notable that the response of hESC-RPE cells was slightly higher than 
that obtained with the ARPE-19 cells (5.1 ± 0.5 vs. 3.4 ± 0.2 pg ml−1), while primary hRPE cells produced clearly 
higher levels of IL-1β when compared to ARPE-19 or hESC-RPE cells alone (30.2 ± 12.0 pg ml−1).
Geldanamycin prevents the inflammasome activation in ARPE-19 and primary human RPE cells. 
Next, we studied the effects of Hsp90 inhibitor geldanamycin (GA) on the activation of the NLRP3 inflammas-
ome. Pre-treatment of primed cells with GA resulted in decreased caspase-1 activity (Fig. 3a) and reduced IL-1β 
release (Fig. 3b) in ARPE-19 cells exposed to MG-132 + BafA. The finding was also verified by replacing the 
Figure 2. MG-132 and bafilomycin A1 (BafA) induce IL-1β secretion in IL-1α-primed ARPE-19 (a), hESC-
RPE (b), and primary human RPE cells (c). The cells were primed in vitro with 4 ng ml−1 of IL-1α for 24 h, 
treated with 5 μM MG-132 for 24 h, and exposed to 50 nM BafA for an additional 24 h. Caspase-1 inhibitor 
(50 µM) was added prior to both MG-132 and BafA where indicated. Untreated cells plated in the same 
numbers and grown under similar conditions served as blank controls, and primed cells (IL-1α) served as 
control groups. Identical volumes of culture medium samples were taken and IL-1β was measured using the 
ELISA technique. Results are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, Mann –Whitney 
U-test to groups with at least four parallel samples.
Figure 3. Geldanamycin (GA) inhibits the NLRP3 activation in ARPE-19 cells. Treatment with GA reduced 
the activity of caspase-1 (a) and the release of IL-1β (b, c). Caspase-1 activity was measured from the cell lysates 
using a commercial kit. IL-1β was measured with ELISA from the MG-132 and bafilomycin A1 (BafA) or 
MG-132 and chloroquine (CHQ)-treated cell culture medium samples. Results are presented as mean ± SEM. 
*P < 0.05, ***P < 0.001, ns = not significant, Mann–Whitney U-test.
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autophagy inhibitor BafA with chloroquine, another lysosomotropic agent that prevents the fusion of autopha-
gosomes with lysosomes and inhibits lysosomal enzymes (Fig. 3c). Moreover, GA returned the IL-1β production 
of MG-132 + BafA-treated primary hRPE cells to a similar level as present in primed cells, which was comparable 
to the effect of treatment with the caspase-1 inhibitor (data not shown). These data provide evidence that GA is 
efficient on preventing the MG-132 + BafA-induced inflammasome activation in human RPE cells. The findings 
remained similar with different autophagy inhibitors (BafA vs. choroquine) as well as on different RPE cell mod-
els (ARPE-19 vs. primary human RPE cells).
NLRP3 becomes degraded by autophagy. In order to study the fate of the NLRP3 released by the Hsp90 
inhibitor, GA was added to cells in different stages of the activation process. The effect of GA was strongest when 
added immediately prior to proteasome inhibition with MG-132 (Fig. 4a). Significantly reduced IL-1β production 
was also detected when GA was added just before inhibition of autophagy by BafA. Conversely, the inhibitory 
effect of GA remained absent when it was added 6 h after BafA (Fig. 4a). In contrast, GA was capable of decreasing 
the secretion of IL-1β regardless of the administration time-point in cells with dysfunctional proteasome clear-
ance after MG-132 treatment alone. (Fig. 4b). It is notable that GA-treated cells showed a significantly reduced 
release of LDH, indicating that the diminished release of IL-1β did not result from cell death (Fig. 4c). Together, 
these data suggest that NLRP3 becomes degraded by autophagy rather than in the proteasomes after its release 
from the Hsp90 complex in human RPE cells. This can be concluded from the data showing that the inhibitory 
effect of GA was visible only when autophagy was still functional (prior to the addition of BafA). Proteasomal 
inhibition was not enough to prevent the NLRP3 activation.
MG-132 + BafA treatment decreases intracellular NLRP3 and increases extracellular NLRP3, 
while GA attenuates these effects. It is known that the inflammasome components can be secreted 
from cells in conjunction with the cytokines, a process which is considered to prevent apoptosis24–30. It is not 
known whether this phenomenon occurs in retinal cells. The priming of ARPE-19 cells with IL-1α significantly 
up-regulated the protein levels of NLRP3 inside the cells (Fig. 5a). However, when inflammasome signaling was 
activated by the subsequent exposure of cells to MG-132 + BafA, the intracellular NLRP3 levels were significantly 
reduced (P < 0.01, Fig. 5a). At the same time, there was a concurrent increase in the levels of extracellular NLRP3 
(P < 0.0001; Fig. 5b). Interestingly, the levels of extracellular NLRP3 were significantly increased also in the pres-
ence of GA, which prevented the inflammasome activation (P < 0.0001; Fig. 5b). Intracellular NLRP3 levels were 
reduced to control levels (Fig. 5a). These results suggest that RPE cells remove activated NLRP3 by secretion, and 
that the same phenomenon also applies to excess levels of the inactive receptor if it cannot be degraded via auto-
phagy. The release of inactive NLRP3 is more moderate when compared to that of the activated receptor but still 
significantly higher when compared to control.
Discussion
In age-related macular degeneration, destruction of the RPE layer results in the death of foveal cone photore-
ceptors that are responsible for the sharp central vision31. This means that RPE cells are critical in the devel-
opment of AMD pathology. Inflammasome signaling has recently been associated with the pathogenesis of 
AMD32–34. This pathway results in the maturation of IL-1β, which we have previously shown to predominate in 
our aggregation model of AMD18. The release of inflammasome-related cytokines is highly dependent on both the 
Figure 4. Geldanamycin (GA) efficiently prevents the IL-1β release until autophagy becomes blocked (a). 
In cells exposed only to the proteasome inhibitor MG-132 GA remains effective irrespective of treatment 
timepoint (b). The reduced release of IL-1β was not caused by increased cell death after GA addition (c). ARPE-
19 cells were exposed to 5 μM MG-132 for 24 h and to 50 nM bafilomycin A1 (BafA) for another 24 h (a). GA 
(0.25 µM) was added prior to MG-132 (a,b), just before BafA, or six hours after BafA (a) or 24 h after MG-132 
(b). IL-1β was measured from medium samples with the ELISA technique. The levels of LDH were measured 
from the cell culture medium using a commercial assay. Results are presented as mean ± SEM. *P < 0.05, 
**P < 0.01, ***P < 0.001, ns = not significant, Mann –Whitney U-test.
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stimulus and the cell type35. We and others have shown that ARPE-19 cells are a poor producer of IL-1β. However, 
we have repeatedly demonstrated the activation of the inflammasome in ARPE-19 cells, showing that these cells 
can serve as a flexible tool enabling extensive screening protocols18,34. In the present study, we confirmed the 
functionality of our aggregation model by demonstrating that the effects previously seen in ARPE-19 cells were 
duplicated in hESC-RPE and primary hRPE cells. Although inflammasome activation can be triggered by com-
bined MG-132 + BafA treatment18, our present data showed that priming with IL-1α enhances that response even 
more. Our data is in line with previous results that IL-1α is capable of inducing pro-IL-1β expression in ARPE-19 
cells3. IL-1α is also a much more potent primer of the NLRP3 inflammasome in ARPE-19 cells than LPS, which 
we used in our previous study with 4-hydroxynonenal34.
Heat shock proteins (Hsps) are chaperones assisting the folding of newly synthetized proteins, repairing mis-
folded proteins, and preventing harmful aggregation36. Hsps 27 and 70 are inducible proteins, whereas Hsp60, 
Hsc70, and Hsp90 are continuously expressed in mammalian cells37. If NLRP3 is translated after the priming sig-
nal, it is removed from the cell unless protected by a protein complex containing Hsp9014–16. Mayor et al. showed 
that in the absence of Hsp90, NLRP3 becomes degraded by the proteasome14. In agreement with their findings, 
in our study, GA reduced the inflammasome-related response, indicating that NLRP3 would be removed without 
the protection proffered by Hsp90. The levels of NLRP3 remained reduced irrespective of the addition of GA 
before or after the proteasomal inhibitor MG-132 in RPE cells, but were unaffected if GA was added after auto-
phagy inhibition. This implies that NLRP3 is degraded also when proteasomes are not working as long as auto-
phagy is functional. Our study differs from the report by Mayor et al. mainly in that their cells were monocytes 
and macrophages. The cell type can indeed affect the outcome, evidence that different tissues and cells throughout 
the body may have their own distinctive reactions to treatment.
As reviewed by Harris et al.38. and observed also by ourselves, autophagy and inflammasomes regulate each 
other, making it most likely that autophagy could be responsible for the removal of unnecessary inflammasome 
components. Autophagy is the ultimate cellular degradation system, especially when proteasomal degradation 
has failed. It is known that proteasomal activity decreases during aging; this process has also been associated with 
the pathogenesis of AMD39,40. Since autophagy is responsible for the degradation of large protein aggregates, it 
could also participate in the removal of inflammasome complexes after activation, as long as it is functional. In 
the aged RPE, material destined for elimination may also be transported by exocytosis. This concept has been 
considered as a potential mechanism to explain the formation of drusen material deposited between the RPE 
cells and the Bruch’s membrane41. Our present data is in line with the studies showing that exocytosis can be an 
alternative and supplementary method for removing NLRP3 released from its protecting complex. Numerous 
studies on different cell types have shown that inflammasome components can be secreted from the cell follow-
ing their activation24–30. This process is considered to prevent cell death, but it has not yet been demonstrated in 
RPE cells. Already in their seminal publication where Martinon et al. introduced the inflammasome, authors 
suggested that the whole inflammasome complex can be secreted out of the cell along with active IL-1β24. That 
work had been performed using LPS-treated THP-1 macrophages. The release of inflammasome components was 
confirmed by Mariathasan et al. using primary macrophages exposed to the intracellular pathogen Salmonella 
typhimurium25. Thereafter, inflammasome components have been shown to be secreted also from UVB-induced 
keratinocytes27 and IMR90 cells undergoing oncogene-induced senescence (OIS)29. Keller et al. showed on 
Figure 5. NLRP3 is secreted from the cells when it cannot be degraded by autophagy. The release of 
NLRP3 is stronger after activation of the NLRP3 inflammasome (concurrent with the release of IL-1β) than 
after inhibition of inflammasome activation by GA (a,b). ARPE-19 cells were treated with IL-1α (24 h), 
geldanamycin (GA) and MG-132 (24 h), and bafilomycin A1 (BafA; 24 h), and both medium and cell lysate 
samples were collected. The intracellular NLRP3 concentration was measured from cell lysates using the 
western blot technique, and a representative blot picture is shown (a). The extracellular NLRP3 levels were 
measured from cell culture medium samples using the ELISA technique (b). Bars are presented as mean ± SEM. 
*P < 0.05, **P < 0.01, ***P < 0.001, ns = not significant, Mann –Whitney U-test.
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activated macrophages and UV-treated keratinocytes that active caspase-1 promotes its own secretion along with 
its substrates28. Oligomeric inflammasome particles released by macrophages have also been shown to function as 
danger signals and spread inflammation to surrounding cells30. Our recent data suggest that especially if NLRP3 
remains non-degraded due to invalid autophagy, it can be released also from RPE cells. It is obvious that NLRP3 
does not leak passively from the cells since the levels of LDH decreased concurrently with the increased IL-1β 
secretion. Although it is evident that MG-132 + BafA causes some damage to the plasma membrane, reflected in 
the increased release of LDH, it is important to note that our IL-1β ELISA kit measures the mature and not the 
pro-form of the cytokine, as we have previously demonstrated18. Furthermore, the significant differences between 
the levels of IL-1β in medium vs. cell lysate18 support the view that MG-132 + BafA-treated cells are functioning 
actively rather than simply passively releasing their contents. Furthermore, neither the caspase-1 inhibitor nor 
GA could prevent the toxicity caused by MG-132 + BafA but still there are significant differences in the released 
cytokine levels, which would be non-existent if cell membranes had simply been ruptured. All of these findings 
support the concept that the release of NLRP3 is intentional and not attributable to passive leakage.
Hsp90 inhibitors have been developed and tested as drugs, especially for treating cancers. Aberrant chaper-
one ligands under pathogenic conditions have been implicated also in many neurodegenerative and aggregation 
diseases, making Hsp90 inhibitors also an interesting therapy option for them42. Hsp90 in the extracellular space 
of RPE induces inflammation, which can be prevented by inhibitors43. Geldanamycin and its synthetic derivative 
17-AAG have been shown to induce Hsp70 expression as well as suppressing protein aggregation and inhibiting 
hypoxia-induced production of factors contributing to neovascularization in RPE cells44–47. All of those proper-
ties would enhance cell survival and combat the pathogenesis of AMD. 17-AAG exerted beneficial effects also 
in murine models of endotoxin-induced uveitis, retinitis pigmentosa, and inherited retinal degeneration48–50. 
Despite these positive findings, many trials have suffered from adverse effects including ocular toxicity accom-
panied by visual disturbances51–54. Our present data reveal a new mechanism and indicate that the regulation of 
Hsp90 would be efficient in reducing inflammasome activation in the RPE. The agent used in our studies, GA, 
is too toxic to be administered to humans and some other entities will need to be tested in subsequent studies. 
One possibility could be the 4-(1H-pyrazolo[3,4-b]pyridine-1-yl)benzamide TAS-116 developed by Japanese 
researchers. TAS-116 is a selective inhibitor of cytosolic Hsp9055. Unlike 17-AAG, 17-DMAG, NVP-AUY922, 
BIIB021, or SNX-2112, TAS-116 does not inhibit other Hsp90 paralogs, such as GRP94 in the endoplasmic retic-
ulum or TRAP1 in mitochondria55. In rats, orally administered TAS-116 did not cause photoreceptor damage, 
and it appeared to be well tolerated also by human RPE cells55.
We have shown here that the blockade of intracellular degradation systems serves as the inflammasome acti-
vator in hESC-RPE and primary hRPE cells, similar to the situation present in ARPE-19 cells. In this improved 
protocol, the priming phase has been consolidated by supplementation with IL-1α. Moreover, the Hsp90 inhibi-
tor GA appeared capable of preventing the NLRP3 inflammasome activation in human RPE cells. NLRP3 released 
from the Hsp90 complex prior to activation was removed by autophagy rather than via proteasomal degradation 
(Fig. 6). The receptor protein was secreted from the cell following its activation, and was partially secreted also 
in its inactive form when it could not be degraded by autophagy. Together, these data increase the knowledge on 
the intracellular receptor-mediated processes critical for the inflammasome activation related to the RPE degen-
eration and its potential as a therapeutic target. Due to its high toxicity, GA cannot be used in clinical settings but 
these studies need to proceed by testing other NLRP3 regulators e.g. less toxic Hsp90 inhibitors.
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